Karen Jean Ferrante - 03 Oct 2022 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Role
Director
Signature
/s/ Evan D. Kearns, Attorney-in-Fact
Issuer symbol
COGT
Transactions as of
03 Oct 2022
Net transactions value
+$13,378
Form type
4
Filing time
04 Oct 2022, 16:30:12 UTC
Previous filing
05 Jul 2022
Next filing
04 Jan 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COGT Stock Option (Right to Buy) Award $13,378 +1,474 $9.08 1,474 03 Oct 2022 Common Stock 1,474 $14.33 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.